Hepatic OATP Drug Transporters and Chemotherapy Disposition
Hepatic OATP Drug Transporters and Chemotherapy Disposition
批准号:
8371734
负责人:
Richard Hsinshin Ho
金额:
$30.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-18 至 2017-08-31
关键词:
ABCB1 geneAccountingAdverse effectsAnimal ModelAntineoplastic AgentsBindingCarrier ProteinsCause of DeathCell membraneCessation of lifeClinicalClinical PharmacologyCorrelative StudyDataDependenceDiagnosisDoseDoxorubicinDrug CompoundingDrug DesignDrug KineticsEffectivenessEvaluationFamilyGeneticGenetic PolymorphismGenetic VariationGoalsHeart DiseasesHepaticHumanImpairmentIn VitroIntestinesInvestigationKidneyKineticsKnockout MiceKnowledgeLinkLiverMalignant NeoplasmsMammalian CellMediatingMedicineMethodsMolecularMolecular WeightMorbidity - disease rateMovementMusOATP TransportersOrganP-GlycoproteinPatientsPharmaceutical PreparationsPharmacodynamicsPharmacogeneticsPharmacologyPlayPropertyRecombinantsRegimenRiskRoleSolubilitySubstrate SpecificitySystemTestingTherapeuticTherapeutic IndexToxic effectTransgenic MiceTransgenic OrganismsUnited StatesVacciniaVacciniumVariantVertebral columnVincristinebasecancer pharmacologycancer therapycancer typechemotherapeutic agentchemotherapyclinically relevantcytotoxicitydocetaxeldrug discoverygenetic profilingimprovedin vivoinsightionizationlipophilicitymouse modelnoveloncologyprospectiveresearch clinical testingresponsesuccessuptake
中文摘要
被称为转运蛋白的细胞膜结合载体蛋白被认为是药物处置的重要因素。这个
英文摘要
Cell membrane-bound carrier proteins called transporters are recognized as important factors in drug disposition. The
Organic Anion Transporting Polypeptides (OATPs) are a superfamily of transporter proteins that facilitate the cellular
uptake of a diverse range of endogenous compounds and drugs and are expressed in organs of importance to drug
disposition, such as the liver, kidney and intestine. Cancer is the second most common cause of death in the US,
exceeded only by heart disease, and accounting for nearly 1 of every 4 deaths. Chemotherapy comprises the backbone
of therapy for most types of cancer. While chemotherapy is a crucial component in the treatment of cancer, its
effectiveness is often mitigated by narrow therapeutic indices which increases the risks for untoward serious adverse
effects associated with administration of such agents. Our preliminary data strongly supports a role for the hepatic
OATPs, OATP1B1 and -1B3, to the disposition of the widely used chemotherapeutic agent docetaxel. Furthermore,
commonly occurring OATP1B1 variants are associated with significant impairment of docetaxel transport, which may
contribute to the oft-witnessed wide interpatient variability in docetaxel pharmacokinetics. Accordingly, we hypothesize
that OATP1B1 and -1B3 play important roles in the hepatic disposition and interindividual variability in drug effect of
commonly used chemotherapeutic agents known to be dependent on hepatic clearance, including docetaxel, vincristine
and doxorubicin. Focused studies that aim to better delineate the kinetic and inhibition profiles, genetic basis for
interindividual variability in drug response, and in vivo pharmacology of OATP1B1 and -1B3 to chemotherapy disposition
are proposed. Specific Aim 1 is focused on determining the pharmacologic roles of OATP1B1 and -1B3 to the hepatic
disposition and clearance of docetaxel, vincristine, and doxorubicin using an in vitro recombinant vaccinia-based method
to express wild-type and variant transporters in a heterologous mammalian cell system. In Specific Aim 2, the
pharmacological relevance of OATP1B1 and -1B3 to the hepatic disposition of docetaxel, vincristine and doxorubicin in
vivo will be evaluated using a humanized transgenic mouse model expressing OATP1B transporters in the background of
the Oatp1b2 knockout mouse. The proposed studies will provide novel and important insights into the roles of the hepatic
OATPs, OATP1B1 and -1B3, to the in vitro and in vivo pharmacology of commonly used chemotherapeutic agents. Long-
term, a more comprehensive understanding of the molecular and clinical pharmacology of hepatic OATPs will have
important implications not only for the evaluation of chemotherapy disposition, toxicity, and efficacy, but also for broad
initiatives such as drug discovery, rational drug design and personalized medicine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Hepatic OATP Drug Transporters and Chemotherapy Disposition
-
批准号:9252034
-
项目类别:
-
资助金额:$15.63万
-
财政年份:2012
-
负责人:Richard Hsinshin Ho
-
依托单位:
Hepatic OATP Drug Transporters and Chemotherapy Disposition
-
批准号:8547081
-
项目类别:
-
资助金额:$36.27万
-
财政年份:2012
-
负责人:Richard Hsinshin Ho
-
依托单位:
Hepatic OATP Drug Transporters and Chemotherapy Disposition
-
批准号:9328094
-
项目类别:
-
资助金额:$30.61万
-
财政年份:2012
-
负责人:Richard Hsinshin Ho
-
依托单位:
Hepatic OATP Drug Transporters and Chemotherapy Disposition
-
批准号:8920601
-
项目类别:
-
资助金额:$21.16万
-
财政年份:2012
-
负责人:Richard Hsinshin Ho
-
依托单位:
Hepatic OATP Drug Transporters and Chemotherapy Disposition
-
批准号:8727619
-
项目类别:
-
资助金额:$37.49万
-
财政年份:2012
-
负责人:Richard Hsinshin Ho
-
依托单位:
Hepatic OATP Drug Transporters and Chemotherapy Disposition
-
批准号:9117587
-
项目类别:
-
资助金额:$30.61万
-
财政年份:2012
-
负责人:Richard Hsinshin Ho
-
依托单位:
MRP2, BSEP, and BCRP Transporter Polymorphisms and Chemotherapy Disposition
-
批准号:7917761
-
项目类别:
-
资助金额:$10.8万
-
财政年份:2009
-
负责人:Richard Hsinshin Ho
-
依托单位:
MRP2, BSEP, and BCRP Transporter Polymorphisms and Chemotherapy Disposition
-
批准号:7892338
-
项目类别:
-
资助金额:$11.97万
-
财政年份:2007
-
负责人:Richard Hsinshin Ho
-
依托单位:
MRP2, BSEP, and BCRP Transporter Polymorphisms and Chemotherapy Disposition
-
批准号:7667453
-
项目类别:
-
资助金额:$11.97万
-
财政年份:2007
-
负责人:Richard Hsinshin Ho
-
依托单位:
MRP2, BSEP, and BCRP Transporter Polymorphisms and Chemotherapy Disposition
-
批准号:8131611
-
项目类别:
-
资助金额:$11.97万
-
财政年份:2007
-
负责人:Richard Hsinshin Ho
-
依托单位:
MRP2, BSEP, and BCRP Transporter Polymorphisms and Chemotherapy Disposition
-
批准号:7474678
-
项目类别:
-
资助金额:$11.97万
-
财政年份:2007
-
负责人:Richard Hsinshin Ho
-
依托单位:
MRP2, BSEP, and BCRP Transporter Polymorphisms and Chemotherapy Disposition
-
批准号:7296720
-
项目类别:
-
资助金额:$11.97万
-
财政年份:2007
-
负责人:Richard Hsinshin Ho
-
依托单位:
海外基金